Abstract
The number of blockbusters continues to increase. The number is set to
increase to 112 in 2007. Of the products set to receive FDA approval this year
and generate blockbuster status on an annual basis, GSK' s Cervarix, intended
for the prevention of infection and lesions from the two cancer-causing types
of HPVs holds great potential.
GSK will earn royalties of up to 10% or $200 million each year from Merck due
to sales of the Cervarix cervical cancer vaccine, according to the legal
settlement reached last year. This is a new market battle and you need to be
part of it.
A joint-venture between Sanofi-Aventis and Merck believe they have first-mover
advantage. Do they? Will GSK be able to fight this advantage in a new
generation of blockbuster vaccines with annual sales likely to exceed $2Bn
each? The companies need to secure their share of this innovative and
lucrative battle ground. Our new report highlights how they plan to do this,
which products will be successful and how you can be part of it. You should
order this report.
GSK believe that comparing Cervarix head-to-head with other vaccines, they can
increase their market share. GSK are confident of this drug. We believe it
will be a blockbuster - what do you think? What should you think? Read this
report to find out.
2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma
virus) to protect against cervical cancer. Cervarix is due to be launched in
2007. Cervarix has, say GSK, the potential to reduce incidence of cervical
cancer by 80%. With 500,000 new cases of cervical cancer reported each year,
cervical cancer is the 3rd-leading cause of cancer death of woman worldwide.
Governments will fund this drug if priced correctly. If this happens then
Blockbuster satus is guaranteed.
The report gives an overview of the potential blockbusters set to hit the
cancer vaccine market. Tn particular concentrating on the following aspects of
cancer vaccines:
- Key players in blockbuster cancer vaccines
- What technologies can be utilised by cancer vaccines
- Revenue forecasts for potential blockbuster cancer vaccines
- Therapeutic cancer vaccines likely to achieve commercial success
- A clear SWOT analysis of cancer drugs
- Competitor analysis of likely blockbuster launches in cancer vaccines
through to 2012
Why you must by this report:
The pharmaceutical industry has been seeking the next blockbuster drug, yet it
appears as though these might not be as profligate as they have been in the
past. However, the cancer vaccine markets hold promise. This report analyses
the current situation in the market and assesses the potential of the products
that are currently in the development pipeline. A comprehensive analysis of
the cancer vaccine market from 2007-2012 outlines the potential of the market.
Visiongain expects to see the development of at least two multi-billion dollar
drugs. You and your company should be part of this market, and you could be by
placing your order immediately.
Unique benefits to you when you order this report:
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using
harddrive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
| 
View Cart
